Wegovy highlights of prescribing information, Novo Nordisk (2024) The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy, Scientific Reports (2024) Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: A nationwide, population-based cohort study, Frontiers in Pharmacology (2022) Most GLP-1 medications correlated with a lower likelihood of anxiety and depression diagnoses, Epic Research (2024) Dopamine release in the midbrain promotes anxiety, Biological Psychology (2021) Dopamine primes the brain for enhanced vigilance, MIT News (2018) Why your cardiologist may prescribe semaglutide (Wegovy), Yale Medicine (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
No batch is released without a signed Certificate of Analysis
Unlike other treatments, tirzepatide targets two key hormonesGLP-1 and GIPthat help regulate appetite and blood sugar
The first structure of a class B GPCR transmembrane (TM) domain was solved recently, but the full length receptor structure is still not well understood
Research has indicated that certain microbes, including Akkermansia muciniphila, Bifidobacterium, and Lactobacillus, can naturally enhance GLP-1 release through several mechanisms
Why Consider Stacking PT-141 and PDE5 Inhibitors
